A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab (ABT-981) in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa
2024-05176-01
2024-11-01
2027-10-09
Klinisk läkemedelsprövning (CTR)
AbbVie Deutschland GmbH & Co. KG
Godkänd
2024-11-07
Diseases [C] - Skin and Connective Tissue Diseases [C17]
Diseases [C] - Immune System Diseases [C20]
Karolinska University Hospital, Region Oerebro Laen
Orebro, Solna
2024-510730-40-00
Therapeutic confirmatory (Phase III)
Forskningspersoner
10
Man, Kvinna
0-17, 65+, 18-64
Historik
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab (ABT-981) in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa
2024-05176-01
2024-11-01
2027-10-09
Klinisk läkemedelsprövning (CTR)
AbbVie Deutschland GmbH & Co. KG
Godkänd
2024-11-07
Diseases [C] - Skin and Connective Tissue Diseases [C17]
Diseases [C] - Immune System Diseases [C20]
Karolinska University Hospital, Region Oerebro Laen
Solna, Orebro
2024-510730-40-00
Therapeutic confirmatory (Phase III)
Forskningspersoner
10
Man, Kvinna
0-17, 65+, 18-64
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab (ABT-981) in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa
2024-08518-02
(ingen förändring)
(ingen förändring)
(ingen förändring)
AbbVie Deutschland GmbH & Co. KG
Godkänd
2025-03-17
(ingen förändring)
Diseases [C] - Immune System Diseases [C20]
Diseases [C] - Skin and Connective Tissue Diseases [C17]
(ingen förändring)
Solna, Orebro
(ingen förändring)
Therapeutic confirmatory (Phase III)
Forskningspersoner
10
(ingen förändring)
(ingen förändring)
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab (ABT-981) in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa
2024-08519-02
(ingen förändring)
(ingen förändring)
(ingen förändring)
AbbVie Deutschland GmbH & Co. KG
Godkänd
2025-03-17
(ingen förändring)
Diseases [C] - Immune System Diseases [C20]
Diseases [C] - Skin and Connective Tissue Diseases [C17]
(ingen förändring)
Solna, Orebro
(ingen förändring)
Therapeutic confirmatory (Phase III)
Forskningspersoner
10
(ingen förändring)
(ingen förändring)
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab (ABT-981) in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa
2025-04949-02
(ingen förändring)
(ingen förändring)
(ingen förändring)
AbbVie Deutschland GmbH & Co. KG
Godkänd med villkor
2025-09-17
(ingen förändring)
Diseases [C] - Skin and Connective Tissue Diseases [C17]
Diseases [C] - Immune System Diseases [C20]
(ingen förändring)
Orebro, Solna
(ingen förändring)
Therapeutic confirmatory (Phase III)
Forskningspersoner
10
(ingen förändring)
(ingen förändring)
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab (ABT-981) in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa
2025-04950-02
(ingen förändring)
(ingen förändring)
(ingen förändring)
AbbVie Deutschland GmbH & Co. KG
Godkänd med villkor
2025-09-17
(ingen förändring)
Diseases [C] - Skin and Connective Tissue Diseases [C17]
Diseases [C] - Immune System Diseases [C20]
(ingen förändring)
Orebro, Solna
(ingen förändring)
Therapeutic confirmatory (Phase III)
Forskningspersoner
10
(ingen förändring)
(ingen förändring)